Reuters·2025-10-30 09:47Core Insights - Danish drugmaker Novo Nordisk has made a higher offer for Metsera to surpass an existing agreement with Pfizer, aiming to strengthen its position in the weight-loss medication market [1] Company Summary - Novo Nordisk is actively pursuing Metsera to enhance its portfolio in weight-loss treatments, indicating a strategic move to consolidate its market presence [1] - The competition with Pfizer highlights the growing interest and investment in the weight-loss medication sector, which is becoming increasingly lucrative [1] Industry Summary - The weight-loss medication market is witnessing heightened competition, with major pharmaceutical companies like Novo Nordisk and Pfizer vying for dominance [1] - This trend suggests a potential increase in innovation and product offerings within the industry as companies seek to capture market share [1]